Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 257049 (Primary) ; Measles and rubella virus vaccine; Retinol; Yellow fever vaccine
Indications Malaria
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

27 Oct 2020 Status changed from active, no longer recruiting to completed.
14 Apr 2020 Planned End Date changed from 18 Dec 2020 to 7 Oct 2020.
16 Mar 2020 Primary(Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049) endpoint has been met as per Results published in the Vaccine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com